WO2021201963A1 - Bronchial denervation using integrated a-mode signal - Google Patents
Bronchial denervation using integrated a-mode signal Download PDFInfo
- Publication number
- WO2021201963A1 WO2021201963A1 PCT/US2021/015825 US2021015825W WO2021201963A1 WO 2021201963 A1 WO2021201963 A1 WO 2021201963A1 US 2021015825 W US2021015825 W US 2021015825W WO 2021201963 A1 WO2021201963 A1 WO 2021201963A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ultrasound
- bronchial
- transducer
- catheter
- ultrasound transducer
- Prior art date
Links
- 230000002638 denervation Effects 0.000 title description 8
- 238000002604 ultrasonography Methods 0.000 claims abstract description 217
- 238000000034 method Methods 0.000 claims abstract description 69
- 210000005036 nerve Anatomy 0.000 claims abstract description 68
- 238000011282 treatment Methods 0.000 claims abstract description 62
- 210000000621 bronchi Anatomy 0.000 claims abstract description 51
- 238000002679 ablation Methods 0.000 claims abstract description 17
- 230000007830 nerve conduction Effects 0.000 claims abstract description 8
- 210000001519 tissue Anatomy 0.000 claims description 32
- 230000001225 therapeutic effect Effects 0.000 claims description 30
- 210000000845 cartilage Anatomy 0.000 claims description 26
- 238000003384 imaging method Methods 0.000 claims description 21
- 239000012530 fluid Substances 0.000 claims description 18
- 230000006378 damage Effects 0.000 claims description 16
- 239000012809 cooling fluid Substances 0.000 claims description 10
- 230000008878 coupling Effects 0.000 claims description 10
- 238000010168 coupling process Methods 0.000 claims description 10
- 238000005859 coupling reaction Methods 0.000 claims description 10
- 238000009826 distribution Methods 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 10
- 230000037431 insertion Effects 0.000 claims description 10
- 238000012544 monitoring process Methods 0.000 claims description 10
- 238000009210 therapy by ultrasound Methods 0.000 claims description 10
- 238000002592 echocardiography Methods 0.000 claims description 8
- 210000003238 esophagus Anatomy 0.000 claims description 8
- 239000013307 optical fiber Substances 0.000 claims description 8
- 239000000523 sample Substances 0.000 claims description 7
- 230000000415 inactivating effect Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 208000028389 Nerve injury Diseases 0.000 claims description 5
- 238000005452 bending Methods 0.000 claims description 5
- 230000008764 nerve damage Effects 0.000 claims description 5
- 238000002627 tracheal intubation Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 230000002779 inactivation Effects 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 210000003437 trachea Anatomy 0.000 claims description 4
- 230000000007 visual effect Effects 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000012634 optical imaging Methods 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 238000012285 ultrasound imaging Methods 0.000 claims description 3
- 238000010304 firing Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 210000001147 pulmonary artery Anatomy 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 11
- 231100000987 absorbed dose Toxicity 0.000 claims 2
- 230000002411 adverse Effects 0.000 claims 1
- 230000003292 diminished effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 abstract description 8
- 208000006673 asthma Diseases 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 238000002716 delivery method Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000002608 intravascular ultrasound Methods 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 210000003492 pulmonary vein Anatomy 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000025721 COVID-19 Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000004323 axial length Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000008035 nerve activity Effects 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000007674 radiofrequency ablation Methods 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 208000020983 Scarring Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 210000003105 phrenic nerve Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000014745 severe cutaneous adverse reaction Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/08—Detecting organic movements or changes, e.g. tumours, cysts, swellings
- A61B8/0833—Detecting organic movements or changes, e.g. tumours, cysts, swellings involving detecting or locating foreign bodies or organic structures
- A61B8/085—Detecting organic movements or changes, e.g. tumours, cysts, swellings involving detecting or locating foreign bodies or organic structures for locating body or organic structures, e.g. tumours, calculi, blood vessels, nodules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/12—Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/42—Details of probe positioning or probe attachment to the patient
- A61B8/4272—Details of probe positioning or probe attachment to the patient involving the acoustic interface between the transducer and the tissue
- A61B8/429—Details of probe positioning or probe attachment to the patient involving the acoustic interface between the transducer and the tissue characterised by determining or monitoring the contact between the transducer and the tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/44—Constructional features of the ultrasonic, sonic or infrasonic diagnostic device
- A61B8/4444—Constructional features of the ultrasonic, sonic or infrasonic diagnostic device related to the probe
- A61B8/445—Details of catheter construction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N7/02—Localised ultrasound hyperthermia
- A61N7/022—Localised ultrasound hyperthermia intracavitary
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
- A61B1/00064—Constructional details of the endoscope body
- A61B1/00071—Insertion part of the endoscope body
- A61B1/0008—Insertion part of the endoscope body characterised by distal tip features
- A61B1/00082—Balloons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00541—Lung or bronchi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
- A61B34/70—Manipulators specially adapted for use in surgery
- A61B34/73—Manipulators for magnetic surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0021—Neural system treatment
- A61N2007/003—Destruction of nerve tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0043—Ultrasound therapy intra-cavitary
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0052—Ultrasound therapy using the same transducer for therapy and imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0082—Scanning transducers
Definitions
- the invention relates to an apparatus and an associated method for the treatment of asthma and other pulmonary indications.
- the invention contemplates the use of a circumferential focused ultrasound field.
- 8,088,127 teaches to denervate by applying RF energy to the bronchial wall with the catheter positioned inside the bronchial lumen. It is proposed to protect the bronchial wall through simultaneous cooling of the wall. This is of course a very time intensive treatment approach since the RF ablation is limited to the electrode contact area. Therefore numerous ablation zones need to be pieced together to obtain a larger ablation zone with increased probability of affecting nerves. Efficacy might be severely limited due to the cooling action. [0005] However, howto selectively target, predominantly nerves, without affecting the bronchial wall and surrounding tissue is not taught in the prior art.
- FIG. 6 Shown in FIG. 6 is an illustration of the bronchial tree.
- FIG. 3 shows a cross section of a bronchial tube surrounded with smooth muscle (7) and nerves (6).
- FIG. 5 shows a longitudinal section of a bronchus (BR) and the adjacent nerves (6).
- the bronchial nerves (6) surround the bronchial tubes. Different individuals have the nerves (6) in different circumferential locations around the bronchial tubes.
- the nerves may be at different radial distances from the central axis of the bronchial tube where the energy emitter (11) is placed (FIG 3). It is not practical to locate the bronchial nerves by referring to anatomical landmarks. Moreover, it is difficult or impossible to locate individual bronchial nerves using conventional in vivo imaging technology. Furthermore, when denervation in the main bronchi is performed, cartilage rings will represent an obstacle in particular for ultrasound ablation. In US Patent Application Publication No. 2016 220851 mechanical means and overlapping ultrasound beams are proposed to seat the ultrasound source so ultrasound energy is applied between or behind cartilage rings. Except for the mechanical seating no apparatus or method is taught as to how to ensure optimal inter cartilage positioning. There is a need for a device and method to easily ensure energy source positioning between cartilage rings. It would be desirable to know whether the ultrasound treatment volume is actually deployed between cartilage rings or whether the ultrasound is reflected by cartilage rings.
- the inability to locate and target the bronchial nerves (6) makes it difficult to interrupt or terminate the bronchial nerve activity using non-surgical techniques without causing damage to the bronchial walls or other side effects. For example, attempts to apply energy to the bronchial nerves can cause stenosis, and necrosis to the bronchi. In addition, the inability to target and locate the bronchial nerves (6) makes it difficult to ensure that bronchial nerve activity has been discontinued enough to achieve an acceptable therapeutic treatment.
- US Patent No. 8,088,127 suggests the use of a radio frequency (“RF") emitter connected to a catheter, which is inserted in the bronchial tree.
- the RF emitter is placed against the bronchial wall and the RF energy is emitted to heat the nerves to a temperature that reduces the activity of bronchial nerves which happen to lie in the immediate vicinity of the emitter.
- the RF emitter source In order to treat all the nerves surrounding the bronchial tubes , the RF emitter source must be repositioned around the inside of each bronchial tube section multiple times. In order to protect the bronchial wall this RF heat application is combined with a cooling application which makes the procedure even more complicated.
- the emitter may miss some of the bronchial nerves, leading to an incomplete treatment.
- the RF energy source electrode
- the RF energy source must contact the bronchial wall to be able to heat the surrounding tissue and nerves, which may cause damage or necrosis to the inner lining of the bronchi.
- the ⁇ 18 patent also suggests the use of high-intensity focused ultrasound to deactivate the bronchial nerves. It is not clear how a High Intensity Focused Ultrasound (HIFU) zone can be aligned with the targeted bronchial nerves. It is difficult or impossible to align this highly focused zone with the bronchial nerves because it is difficult or impossible to visualize and target the bronchial nerves with current technology, and because the bronchial nerves may lie at different radial distances and circumferential locations from the central axis of bronchi. The latter problem is aggravated in patients who have bronchi with large variations in shape or thickness. Moreover, the focal point can encompass only a small segment of each bronchial nerve along the lengthwise direction of the bronchi. Since nerves tend to re-grow, a small treatment zone allows the nerves to reconnect in a shorter period of time.
- HIFU High Intensity Focused Ultrasound
- ultrasound has been used to enhance cell repair, stimulate the growth of bone cells, enhance delivery of drugs to specific tissues, and to image tissue within the body.
- high-intensity focused ultrasound has been used to heat and ablate tumors and tissue within the body. Ablation of tissue has been performed nearly exclusively by high-intensity focused ultrasound because the emitted ultrasound energy is focused on a specific location to allow precise in- depth tissue necrosis without affecting surrounding tissue and intervening structures that the ultrasound energy must pass through.
- US Patent No. 6,117,101 to Diederich, discusses use of highly collimated ultrasound energy rather than high intensity focused ultrasound for ablating tissue to create a scar ring within the pulmonary vein for blocking the conduction of electrical signals to the heart (pulmonary vein isolation).
- One aspect of the invention provides an apparatus for inactivating bronchial nerve conduction in a human or non-human mammalian subject.
- the apparatus according to this aspect of the invention preferably includes an ultrasound transducer adapted for insertion into the bronchial system of the mammalian subject.
- the ultrasound transducer desirably is arranged to transmit a ring of focused ultrasound energy (see FIGS. 8A-8C and 12).
- the apparatus according to this aspect of the invention desirably also includes an actuator which is electrically connected to the transducer.
- the actuator most preferably is adapted to control the ultrasound transducer to transmit focused ultrasound energy into an impact volume of at least approximately 1 cm 3 , encompassing the bronchial tube so that the circumferentially focused ultrasound energy is applied at a therapeutic level sufficient to inactivate conduction of bronchial nerves throughout the impact volume.
- This energy level is about 1/10 of the energy level typically applied for tissue necrosis.
- therapeutic level is below the level required for tissue ablation.
- the apparatus may further include a catheter with a distal end and a proximal end, the transducer being mounted to the catheter adjacent the distal end, the transducer being constructed and arranged inside a compliant balloon which will make contact with the bronchial wall.
- This compliant balloon is filled with a circulating cooling fluid to conduct ultrasound energy from the transducer to the bronchial walls and surrounding tissue and nerves. This cooling fluid also transports excessive heat away. from the transducer. About half of the electrical energy supplied to the transducer is converted into heat while the other half is converted to ultrasonic energy.
- the energy levels and balloon diameters must be adjusted in accordance with the diameter of the bronchus at the ablation site. If these parameters are not adjusted (i.e., if there is a constant energy setting for all bronchial diameters), there is a significant risk of either too much damage caused by the ultrasound ablation or not enough energy to properly ablate and denervate the lung. Therefore, in order to work with a range of bronchial diameters, the device must be enabled to adjust power settings of ultrasound based upon the diameter of the bronchial airway.
- the device must also be enabled to detect whether circumferential balloon/bronchus contact is complete or partial.
- the transducer may be configured to transmit the ultrasound energy in a 360° cylindrical pattern surrounding a longitudinal transducer axis, and the catheter may be constructed and arranged to hold the axis of the transducer generally parallel to the axis of the bronchial tube.
- Focusing mechanisms can be electronic as in a phased array or include a fluid lens 12' (FIG: 8B) or a mechanical lens 322 (Fig. 8C).
- a fluid lens implemented by a suitable configured balloon 12' as shown in FIG. 8B
- the diameter of the focal ring can be varied with balloon pressure by changing the shape of the compliant balloon 12' with pressure and therewith changing the lens effect.
- the electronic focusing can also be adjusted based on the bronchial (i.e. balloon) diameter which can be calculated from balloon pressure as shown in FIG.10A or through ultrasound pinging (see FIGS. 10B and 11).
- FIG. 12 Another alternative is a rotating single crystal or annular array transducer 11" (as shown in FIG. 12) as used in mechanical IVUS systems (i.e. BSX).
- Therapeutic ultrasound pulses and/or full rotations could be interleaved with imaging pulses to generate quasi simultaneous imaging/therapy modes.
- annular array transducer 11" as shown in FIG. 12 When an annular array transducer 11" as shown in FIG. 12 is utilized very high resolution images can be obtained. For denervation applications it is advisable to defocus the therapeutic annular array beam to a certain degree in order to avoid harmful energy densities in the focal zone and to ensure sufficiently large treatment volumes in order to maximize efficacy.
- the system circulating the coupling/cooling fluid may measure the fluid volume and pressure and therewith determine the bronchial diameter, see FIG.
- a further aspect of the invention provides methods for inactivating bronchial nerve conduction in a mammalian subject.
- a method according to this aspect of the invention desirably includes the steps of inserting an ultrasound transducer into a bronchial branch of the subject and actuating the transducer to transmit therapeutically effective ultrasound energy into an circular impact volume of at least approximately 1 cm 3 encompassing the bronchial branch.
- the ultrasound energy desirably is applied so that the therapeutically effective ultrasound energy inactivates conduction of all the nerves in the impact volume.
- the step of actuating the transducer may be so as to maintain the temperature of the bronchial wall below 65°C while heating the solid tissues within the impact volume, including the nerves in the impact volume, to above 42°C.
- the preferred methods according to this aspect of the invention can be performed successfully without determining the actual locations of the bronchial nerves, and without targeting or focusing on the bronchial nerves.
- the treatment can be performed without measuring the temperature of tissues.
- the treatment preferably is performed without causing injury to the bronchi.
- FIG. 1 is partially an anatomical view of typical main bronchial trunks B L and B R and associated structures and partially a block diagram of a system for treatment of pulmonary conditions, in accordance with the present invention .
- FIG. 2 is partially a side elevational view of a treatment catheter 10 advanced through a bronchoscope 5 into the right bronchial branch and a bronchial sectional view, diagrammatically depicting an ultrasound treatment volume 13.
- FIG. 3 is a schematic transverse cross sectional view through a bronchial tube with an ultrasound transducer 11 in the center surrounded by cooling fluid in a compliant balloon.
- FIGS. 4A and 4B are a partial side elevational view of treatment apparatus and a partial longitudinal cross-sectional view of a bronchial tube, demonstrating the effects on power distribution of proper alignment in FIG. 4A in contrast with a non-centered, non-aligned ultrasound transducer in FIG. 4B
- FIG. 5 is a side elevational view of a right bronchial branch showing adjacent nerves running alongside the bronchial tube:
- FIG. 6 is a schematic elevational view showing a bronchial tree in its entirety.
- FIG. 7 is a flowchart depicting steps in treating the bronchi pursuant to the present invention.
- FIG. 8A-8C are diagrams illustrating different focusing mechanisms for an ultrasound catheter for use in a method in accordance with the present invention.
- FIG. 9A through 9E are diagrams depicting respective catheter delivery methods without the use of a bronchoscope.
- FIG. 10A is a graph relating to a pressure measurement technique for determination of bronchial diameter.
- FIG. 10B is a schematic side elevational view of a device in accordance with the invention for use in determining bronchial diameters through ultrasound pinging.
- FIG. 11 is a schematic cross-sectional view of a non-circular bronchus, together with a graph depicting ultrasound pinging in the bronchus pursuant to the invention.
- FIG. 12 is a schematic cross-sectional view of a rotary treatment and imaging catheter in accordance with the invention.
- FIGS. 13A and 13C are cross sectional views of a main bronchus with an inserted ultrasound catheter with longitudinal position sensing and position optimization, showing the catheter and particularly an ultrasound transducer and balloon at different longitudinal positions in the bronchus, relative to cartilage rings thereof.
- FIGS. 13B and 13D are graphs showing magnitudes of integrated A mode ultrasound echoes for the positions of the ultrasound catheter, transducer and balloon as shown in FIGS. 13A and 13C, respectively.
- FIG. 14A is a diagram of a portion of the left (301) and right (302) main bronchus of a person's bronchial tree, showing the aorta (304) and an air filled balloon (315) positioned in the esophagus (303) to allow for esophageal distance determination.
- FIG. 14B is a graph of intensity of an integrated ultrasound echo signal as a function of time after an ultrasound pulse emission in the configuration of FIG. 14A.
- FIGS 15A and 15B are graphs showing magnitudes of integrated A mode signals for complete (15A) and incomplete (15B) balloon-bronchus coupling.
- Apparatus according to one embodiment of the invention is advanced through the working channel of a bronchoscope 5.
- an ultrasound catheter 10 can be advanced through a sheath or directly without any delivery instrument (FIG. 1) through an oral intubation device.
- the sheath or ultrasound catheter 10 generally may be in the form of an elongated tube having a proximal end, a distal end and a proximal-to-distal axis.
- the term “distal” refers to the end which is inserted into the body first, i.e., the leading end during advancement of the element into the body, whereas the term “proximal” refers to the opposite end.
- the sheath or ultrasound catheter may be a steerable sheath or catheter.
- the sheath or catheter may include known elements such as one or more pull wires (not shown) extending between the proximal and distal ends of the sheath or catheter and connected to a steering control arranged so that actuation of the steering control by the operator flexes the distal end of the sheath or catheter in a direction transverse to the axis.
- the sheath or the ultrasound catheter 10 might be inserted into either the left bronchus B L or the right bronchus B R (FIG. 1) through an oral intubation device 202 as shown for a directly delivered ultrasound catheter 10 in FIG. 9B.
- One of the delivery techniques might include an optical fiber 203 within the steerable sheath or within a central lumen of the ultrasound catheter. Once the main bifurcation has been passed, which can be seen through the optical fiber, one of the treatment areas has been reached and the optical fiber 203 is withdrawn from the sheath and replaced with the ultrasound treatment catheter 10 which is advanced as far as the optical fiber insertion length.
- Another delivery method relies on a length marking 204 (FIG.
- FIG. 9B Yet another delivery variant is to measure the degree of bending of the distal catheter portion though strain gages 206 (FIGS. 9C and 9D).
- the catheter 10 will be relatively straight as long as located in the trachea. A high degree of bending will be measured once the distal catheter portion is positioned distal to the main bifurcation MB in the right branch B R (or left branch B L) as indicated in FIG 9D.
- Another delivery method is to monitor the bronchial diameters through either inflation of balloon 12, FIG. 10B, or ultrasound measurement, as shown in FIG. 11. As soon as the diameter measures significantly less (about 50%) the main bifurcation has been passed, as indicated in FIG. 9E.
- the apparatus includes the catheter 10 having a proximal end, a distal end and a proximal-to-distal axis which, in the condition depicted in F
- Catheter 10 has compliant balloon 12 mounted at the distal end. In its inflated condition (FIGS. 2 and 3), balloon 12 engages the bronchial wall and therewith allows for ultrasound to be conducted from transducer 11 into bronchial wall and surrounding tissues 7 (FIG. 3).
- Ultrasound transducer 11 (FIG. 3) is mounted adjacent the distal end of catheter 10 within balloon 12.
- Transducer 11. which is desirably formed from a ceramic piezoelectric material, is of a tubular shape and has an exterior emitting surface in the form of a cylindrical surface of revolution about the proximal-to-distal axis of the transducer 11.
- the transducer 11 typically has an axial length of approximately 2 and approximately 10 mm, and preferably about 6 mm.
- the outer diameter of the transducer 11 is approximately 1.5-3 mm in diameter, and preferably 2 mm.
- the transducer 11 also has conductive coatings (not shown) on its interior and exterior surfaces.
- the transducer may be physically mounted on a metallic support tube (not shown) which in turn is mounted to the catheter 10.
- the coatings are electrically connected to ground and signal wires.
- Wires 110 extend from the transducer 11 through a lumen in the catheter 10 to a connector 102 electrically coupled with the ultrasound system.
- the lumen (not designated) extends between the proximal end and the distal end of catheter 10, while the wires 110 extend from the transducer 11, through the lumen, to the proximal end of the catheter 10.
- Transducer U is arranged so that ultrasonic energy generated in the transducer is emitted principally from the exterior or outer surface (not separately designated).
- the transducer may include features arranged to reflect ultrasonic energy directed toward the interior of the transducer so that the reflected energy, travelling outwardly, reinforces the ultrasonic vibrations at the exterior surface.
- the support tube and transducer 11 may be configured so that the energy emitted from an interior surface of the transducer 11 is redirected outwardly to enhance the overall efficiency of the transducer.
- the ultrasound energy generated by the transducer 11 is reflected at the interior mounting to reinforce ultrasound energy propagating from the transducer 11 , thereby ensuring the ultrasound energy is directed outwardly from an external surface of the transducer 11.
- Transducer 11 is also arranged to convert ultrasonic waves impinging on the exterior surface into electrical signals on wires 110. While A-mode signals integrated over the treatment volume cannot provide for spatial resolution like with an imaging transducer, a conclusion about the bronchial lumen can be made based on the magnitude of the amplitude and distance (time) of the volume-integrated A-mode signal. If the reflecting structure is not perfectly circular, the width of the reflected signal will be mathematically related, e.g., proportional, to the difference between a largest bronchial diameter dmax and a smallest diameter dmin (see FIG. 11). Stated another way, transducer 11 can act either as an ultrasonic emitter or an ultrasonic receiver.
- the receiving mode is of particular importance for an array type transducer as described in U.S. Patent Application No. 14/770,941 , Publication No. 2016/0008636, because with an array type transducer 11 the received echoes can be electronically focused, using phased array processing, and high resolution images can be achieved.
- the transducer 11 is designed to operate, for example, at a frequency of approximately 1 MHz to approximately a few tens of MHz, and typically at approximately 10 MHz. The actual frequency of the transducer 11 typically varies somewhat depending on manufacturing tolerances.
- the optimum actuation frequency of the transducer may be encoded in a machine-readable or human- readable element (not shown) such as a digital memory, bar code or the like affixed to the catheter.
- the readable element may encode a serial number or other information identifying the individual catheter, so that the optimum actuation frequency may be retrieved from a central database accessible through a communication link such as the internet.
- An ultrasound system also referred to herein as an actuator, is releasably connected to catheter 10 and transducer 11 through a plug connector 102 (FIG. 1).
- a control unit 104 and an ultrasonic signal or waveform generator 106 are arranged to control the amplitude and timing of the electrical signals so as to control the power level and duration of the ultrasound-frequency signals emitted by transducer 11.
- An energization circuit 100 including control unit 104 and ultrasonic signal generator 106 also includes a detection subcircuit 108 arranged to detect electrical signals generated by transducer 11 and transmitted via wires 110 and communicate such signals to the control unit 104.
- detection subcircuit 108 includes a receiver or echo signal extractor 112, a digitizer 114, an ultrasonic echo signal preprocessor 116, and an image analyzer 118 connected in series to one another.
- Ultrasonic signal generator 106 produces both therapeutic denervation signals and outgoing diagnostic imaging signals.
- the outgoing imaging signals and the returning echo signals may be transmitted and picked up by a circular array 120 of transducer elements 122 operating as a phased array.
- Transducer 11 may thus include an axial array of circular arrays 120 of transducer elements 122.
- a multiplexer or switching circuit 124 is operated by control unit 104 to switch to a receiving mode after imaging signals are emitted during a transmitting mode via a digital-to-analog converter 126 and a transmitter module 128.
- a circulation device 212 is connected to lumens (not shown) within catheter 10 which in turn are connected to balloon 12.
- the circulation device 212 is arranged to circulate a liquid, preferably an aqueous liquid, through the catheter 10 to the transducer 11 in the balloon 12.
- the circulation device 212 may include elements such as a tank 214 for holding the circulating coolant, pumps 216, a refrigerating coil 218, or the like for providing a supply of liquid to the interior space of the balloon 12 at a controlled temperature, desirably at or below body temperature.
- the control unit 104 interfaces with the circulation device 212 to control the flow of fluid into and out of the balloon 12.
- the control unit 104 may include motor control devices 220 linked to drive motors 222 associated with pumps 216 for controlling the speed of operation of the pumps.
- Such motor control devices 220 can be used, for example, where the pumps 216 are positive displacement pumps, such as peristaltic pumps.
- the control unit 104 may operate structures such as controllable valves 224 connected in the fluid circuit for varying resistance of the circuit to fluid flow.
- the ultrasound system may further include pressure sensors 226 (FIG. 1), to monitor the liquid flow through the catheter 10 and determine the bronchial diameter as shown in FIG. 10A by detecting the point of pressure increase without significant volume increase which corresponds with the balloon reaching full inflation inside the bronchus B L or B R .
- the corresponding diameter can be determined through a look-up table, for instance, in a memory connected to control unit 104, where volume/pressure values are related to diameters.
- At least one pressure sensor 226 monitors the flow of the liquid to the distal end of catheter 10 to determine if there is a blockage while another pressure sensor 226 monitors leaks in the catheter 10. While the balloon 12 is in an inflated state, the pressure sensors 226 and 228 maintain a desired pressure in the balloon preferably so that the compliant balloon occludes the bronchus B L or B R .
- the ultrasound system 100 incorporates a reader 228 for reading a machine-readable element on catheter 10 and conveying the information from such element to the control unit or board 104.
- the machine-readable element on the catheter may include information such as the operating frequency and efficiency of the transducer 11 in a particular catheter 10, and the control unit 104 may use this information to set the appropriate frequency and power for exciting the transducer.
- control unit 104 may be arranged to actuate an excitation source or frequency scanner 230 to measure the transducer operating frequency by energizing the transducer at a low power level while scanning the excitation frequency over a pre-determined range of frequencies for example 8.5Mhz-10.5Mhz, and monitoring the response of the transducer 11 to such excitation and to select the optimal operating frequency.
- an excitation source or frequency scanner 230 to measure the transducer operating frequency by energizing the transducer at a low power level while scanning the excitation frequency over a pre-determined range of frequencies for example 8.5Mhz-10.5Mhz, and monitoring the response of the transducer 11 to such excitation and to select the optimal operating frequency.
- the ultrasonic system may be similar to that disclosed in U.S. Patent Application No. 14/770,941, Publication No. 2016/0008636 , the disclosure of which is incorporated by reference herein.
- a method according to an embodiment of the present invention is depicted in flowchart form in FIG. 7. After preparation of a human or non-human mammalian subject such as a patient
- the ultrasound catheter 10 is inserted into the working channel of the bronchoscope (step 1206) after the bronchoscope has been advanced (steps 1202, 1204) to the desired treatment site under visual guidance through the bronchoscope camera or optical fiber.
- a steerable sheath preferably with ultrasound imaging capability as described in U.S. Patent Application No. 14/770,941, Publication No. 2016/0008636, can be used as a delivery channel for the treatment catheter.
- the treatment catheter is equipped with a steering or deflection mechanism and can be advanced directly to the treatment site as shown in FIG 1. If the catheter combines imaging and therapeutic capabilities as described in the U.S. Patent Application No.
- this delivery method enables the fastest procedure time and is easily tolerated by the patient.
- a guide wire 14 in FIG. 2 to be delivered through the working channel of the bronchoscope to the treatment site and the ultrasound treatment catheter to be advanced over the wire after the bronchoscope has been withdrawn. This technique will allow for very small, flexible bronchoscopes to be utilized.
- pumps bring balloon 12 to an inflated condition (steps 1210 and 1212 in FIG. 7) as depicted in FIGS. 2 and 3.
- the compliant balloon 12 engages the bronchial wall, and thus centers transducer 11 within the bronchial branch, with the axis of the transducer 11 approximately coaxial with the axis of the bronchial branch.
- This not only provides for a relatively homogeneous energy distribution circumferentially, but also keeps the very high energy levels close to the transducer located inside the cooling fluid where they are harmless, since ultrasound does not interact with fluid (see FIG. 4).
- FIGS. 4A and 4B where in FIG. 4A the ultrasound transducer 11 is properly centered and the energy is distributed without causing injury to the wall of the bronchus B L or B r .
- FIGS. 4A and 4B Another advantage of proper centering is that the treatment volume coincides with the relatively flat portion of the 1/R curve, providing an almost constant power level throughout the treatment volume.
- FIG. 4B the transducer 11 is not centered, resulting in uneven power distribution circumferentially.
- the transducer 11 is positioned off axis (due to too small a balloon diameter) which exposes the bronchial wall to a peak power level which may cause wall injury.
- the circulation apparatus including pump 216, coils 218, and valves 224 (FIG. 1), maintains a flow of cooled aqueous liquid into and out of balloon 12, so as to cool the transducer 11.
- the cooled balloon 12 also tends to cool the interior surface of the bronchus B L , B R .
- the liquid flowing within the balloon 12 may include a radiographic contrast agent to aid in visualization of the balloon and verification of proper placement under fluoroscopy.
- the ultrasound system uses transducer 11 to measure the size of the bronchus B L , B R (see FIG. 6).
- the control unit 104 and ultrasound source or ultrasonic signal generator 106 actuate the transducer 11 to "ping" the bronchus with a low-power ultrasound pulse as shown in FIG. 11.
- the ultrasonic waves in this pulse are reflected by the bronchial wall onto transducer 11 as echoes.
- Transducer 11 converts the echoes to electrical echo-encoding signals.
- the ultrasound system particularly control unit 104 (which typically takes the form of a programmed general-purpose computer or a hard wired processor), then determines the diameter of bronchus B L or B R by analyzing the echo signals. For example, the ultrasound system may determine the time delay between actuation of the transducer 11 to produce the "ping" and the return of echo signals.
- the width of the return signal represents the difference between diameter dmax and diameter dmin in case the bronchial section is not perfectly circular but oval shaped (see FIG. 11).
- the ultrasound system uses the measured bronchus size to set the acoustic power to be delivered by transducer 11 during application of therapeutic ultrasonic energy in later steps.
- the control board or unit 104 may use a lookup table correlating a particular echo delay (and thus bronchial diameter) with a particular power level. Generally, the larger the diameter, the more power should be used.
- the volume integrated echo will also represent coupling of the balloon with the bronchial wall as shown in FIGS 15A and 15B. If air is trapped the echo amplitude of the balloon/bronchus interface will be significantly larger as shown in FIG 15B than in case of complete circumferential coupling as shown in FIG 15A.
- the volume integrated A-mode signal can also be analyzed to detect any air filled spaces in the treatment volume as shown in FIG. 14A, i.e., an air filled esophagus 303, due to an air filled balloon catheter 315 placed in the esophagus 303.
- the air filled balloon 315 proximate a distal end of the transducer-bearing catheter 10, registers as an artifact in the volume-integrated A-mode signal as shown in the graph of FIG 14B.
- the treatment catheter 10 will be advanced more distally in the bronchus B L or B R until the esophagus signal or artifact disappears or in other words the esophagus is located outside of the treatment volume.
- the air in the esophageal balloon 315 can be replaced with a circulating cooling fluid after distance detection to further reduce the chances of collateral esophageal damage. Otherwise, esophageal fistulae and/or peri-esophageal vagus nerve damage could result.
- the volume integrated A-mode signal can also be analyzed to optimize positioning of the energy source or transducer 11 so that the portion of the ultrasound reflected by cartilage rings CR is minimized and the ultrasound treatment volume is positioned in a plane BC mainly between cartilage rings CR.
- FIG. 13A shows catheter 10, transducer 11 and balloon 12 positioned within a cartilage ring CR, that is, in a transverse plane of the cartilage ring.
- FIG. 13C depicts catheter 10, transducer 11 and balloon 12 positioned in a transverse plane BC between adjacent cartilage rings CR. .
- Optimized positioning is obtained by analyzing the volume integrated A-mode signal and minimizing a circumferentially integrated cartilage echo Uc by moving the catheter 10, moving the transducer 11 inside the balloon 12 or by electronic selection of transducer sections as shown in FIG. 8A.
- echo signal Uc will occur distally to a bronchial wall signal Ub.
- the positioning is here controlled directly by detecting cartilage echoes and adjusting the longitudinal position of ultrasound source transducer 11 to optimally deliver the ultrasound energy in between cartilage rings CR.
- the complete catheter can be moved longitudinally until echo signal Uc is minimal or the transducer inside the balloon can be moved until echo signal Uc is minimal.
- transducer segments or groups thereof are activated until echo signal Uc is minimized and therewith an optimal positioning between cartilage rings CR has been obtained.
- the inserting of the ultrasound transducer 11 into the bronchial tree may be performed by any of the methods herein described, including (i) through a working channel of a bronchoscope under visual guidance, (ii) through a steerable sheath, (iii) with a steerable ultrasound catheter through an oral intubating device, (iv) under optical imaging guidance with an optical fiber inserted through the central lumen of the steerable ultrasound treatment catheter, and (v) without a sheath or bronchoscope, directly through an oral intubation device with a steerable ultrasound catheter with a distance scale marking for monitoring degree of insertion after conducting a CT, RI procedure to ascertain distance along a bronchial tree to the bronchial section.
- the ultrasound transducer may be mounted to a distal end of a catheter, the inserting of the ultrasound transducer into the bronchial tree includes inserting the catheter so that the ultrasound transducer is placed at a desired operating position determined at least in part based on a bending radius of a distal catheter portion monitored via strain gages. Desired catheter position may be determined in part by monitoring the diameters of trachea and bifurcated bronchi, as described herein.
- the physician initiates the treatment through a user interface (not illustrated).
- the ultrasonic system or actuator and particularly the control board or unit 104 and ultrasonic signal source or generator 106, energizes transducer 11 to deliver therapeutically effective ultrasonic waves to an impact volume 13 (FIG.
- the ultrasound energy transmitted by the transducer 11 propagates generally radially outwardly and away from the transducer 11 encompassing a full circle, or 360° of arc about the proximal-to-distal dimension or longitudinal axis of the transducer 11 and the axis of the bronchial section treated.
- the selected operating frequency, focus-characteristic, placement, size, and the shape of the ultrasound transducer 11 allows the entire bronchial section and bronchial nerves to lie within the " focal field" of the transducer 11.
- an outwardly spreading, focused omni-directional (360°) cylindrical field of ultrasound waves is generated by the transducer 11 .
- the radial extent of the near field region, in which the beam can be focused is defined by the expression L 2 /l, where L is the axial length of the transducer 11 and l is the wavelength of the ultrasound waves.
- the beam begins to spread axially to a substantial extent.
- the beam does not spread axially to any substantial extent (FIG. 2) but can be focused.
- focused refers to a beam, which increases in intensity in the direction of propagation of the beam away from the transducer 11 .
- the impact volume 13 is generally cylindrical and coaxial with the bronchial section treated (FIG. 2).
- the impact volume extends from the balloon exterior or outer surface to an impact radius, where the intensity of the ultrasonic energy is too small to heat the tissue to the temperature range that will cause inactivation of nerves.
- the length of the transducer 11 may vary between 2 mm and 10 mm, but is preferably 6 mm, to provide a wide aperture to enable focusing.
- the diameter of the transducer 11 may vary between 1.5 mm and 3.0 mm, and is preferably about 2.0 mm.
- the dosage is selected not only for its therapeutic effect, but also to allow the radius of the impact volume (focal zone) 13 to be preferably less than 5 mm from the balloon surface in order to encompass the bronchial section treated and adjacent bronchial nerves, all of which lie within an average radius of less than 5 mm from the balloon surface, without transmitting damaging ultrasound energy to collateral structures like esophagus 3, shown in FIG. 1 and 303 in FIG14A.
- the power level desirably is selected so that throughout the impact volume , solid tissues are heated to about 42°C or more for several seconds or more, but desirably all of the solid tissues, including the wall of the bronchus remain well below 65°C.
- the solid tissues including all of the bronchial nerves
- the solid tissues are brought to a temperature sufficient to inactivate nerve conduction but below that which causes rapid necrosis of the tissues.
- the dosage of ultrasonic energy desirably is also less than that required to cause substantial shrinkage of collagen in the impact volume. Operation of the transducer thus provides a therapeutic dosage, which inactivates nerves without causing damage to the bronchus B L or B R .
- the circulation of cooled liquid through the balloon 12 containing the transducer 11 may also help reduce the heat being transferred from the transducer 11 to the inner layer of the bronchus. Hence, the transmitted therapeutic focused ultrasound energy does not damage the inner layer of the bronchus, providing a safe treatment.
- the acoustic power output of the transducer 11 typically is approximately 10 watts to approximately 100 watts, more typically approximately 20 to approximately 50 watts.
- the duration of power application typically is approximately 2 seconds to approximately a minute or more, more typically approximately 10 seconds to approximately 20 seconds.
- the optimum dosage used with a particular system to achieve the desired temperature levels may be determined by mathematical modeling or animal testing.
- the impact volume 13 of the focused ultrasound energy encompasses the entire bronchial section treated and closely surrounding tissues, and hence encompasses all of the bronchial nerves surrounding the bronchus B L or B R . Therefore, the placement in the bronchus B u B R of the transducer 11 may be indiscriminate in order to inactivate conduction of all the surrounding bronchial nerves 6 (see FIGS. 3 and 5) surrounding the bronchi in the subject.
- "indiscriminate” and “indiscriminately” mean without targeting, or locating on, any specific bronchial nerves. If the ablation is performed in the main bronchi, the ultrasound source position will be optimized to lay between cartilage rings as described above with reference to FIGS. 13A to 13D.
- the physician may then reposition the catheter 10 and transducer 11 along the bronchus B L , B R and reinitiate the treatment to retransmit therapeutically effective focused ultrasound energy.
- This inactivates the bronchial nerves at an additional location along the length of the bronchial tree (FIG. 6), and thus provides a more reliable treatment.
- the repositioning and retransmission steps optionally can be performed multiple times.
- the physician moves the catheter 10 with the transducer 11 to the other main bronchus (B L , B R ) and performs the entire treatment again for that bronchial side (see FIG. 6). After completion of the treatment, the catheter 10 is withdrawn from the subject's body.
- the ultrasound system may control the transducer 11 to transmit ultrasound energy in a pulsed function during application of therapeutic ultrasonic energy.
- the pulsed function causes the ultrasound transducer 11 to emit the ultrasound energy at a duty cycle of, for example, 50%. Pulse modulation of the ultrasound energy is helpful in limiting the tissue temperature while increasing treatment times which will result in a more homogenous or even temperature distribution throughout the treatment volume.
- the pulsed therapeutic function can also be interleaved with a diagnostic imaging mode when the ultrasound transducer comprises an array of separately activatable transducer elements instead of a single unitary cylindrical transducer. This way diagnostic ultrasound imaging can be obtained essentially or quasi simultaneously with the therapeutic treatment, see U.S.
- the steps of measuring the bronchial size and adjusting the dose may be omitted.
- the transducer is simply operated at a preset power level sufficient for the bronchial diameters of an average subject.
- the bronchial diameters can be measured by techniques other than actuation of transducer 11 as, for example, by radiographic imaging or magnetic resonance imaging, fiber optic imaging or use of a separate ultrasonic imaging catheter. In this instance, the data from the separate measurement can be used to set the dose.
- the balloon 12 may be formed from a porous membrane or include holes, such that cooled liquid circulated within the balloon may escape or flow from the balloon 12 against the bronchial walls to improve acoustic contact.
- catheter 10 is a disposable, single-use device.
- the catheter 10 or ultrasonic system may contain a safety device that inhibits the reuse of the catheter 10 after a single use.
- a safety device that inhibits the reuse of the catheter 10 after a single use.
- Such safety devices per se are known in the art.
- the catheter 10 itself may include a steering mechanism which allows the physician to directly steer the distal end of the catheter. In this case a bronchoscope or sheath may be omitted.
- an ultrasound energy emitter unit at the distal end of the catheter which includes the ultrasound transducer, may be positioned in adjacent structures like the pulmonary artery or aorta (4 in FIG. 1 and 304 in FIG 14A), and the ultrasound transducer may include reflective or blocking structures for selectively directing ultrasound energy from the transducer over only a limited range of radial directions toward the bronchial nerves.
- the ultrasound energy is directed into a segment or beam propagating away from an exterior surface of the transducer, commonly known as a side firing transducer arrangement.
- the ultrasound transducer may have a construction and be operated to emit as an ultrasound array and directed ultrasound energy under image guidance similarly as disclosed in U.S. Patent Application No. 14/770,941, Publication No. 2016/0008636, incorporated by reference herein.
- the route by which the catheter is introduced into the body, and then positioned close to the bronchus is varied from the bronchial approach discussed above.
- FIG. 8A shows a multiple-element version of transducer 11 comprising a plurality of circular transducer elements 11 ' which can be activated individually or in combination.
- each circular transducer element 11 1 may take the form of a circular array 120 of transducer elements 122 operating as a phased array.
- Transducer elements 11' may thus constitute an axial array of circular arrays of transducer elements.
- multiplexer or switching circuit 124 (FIG. 1) may switch between receiving and transmitting during an imaging mode of operation, so as to receive ultrasonic echoes or reflected waveforms after imaging signals are emitted via digital-to-analog converter 126 and transmitter module 128.
- control unit 104 causes the phased array of transducer elements 11' (FIG. 8A) to focus ultrasound energy in an annular treatment zone 320 containing nerves to be deactivated.
- Control unit 104 again, may be a hard wired processor or a programmed general purpose computer or microprocessor. Also in response to signals from control unit 104, multiplexer or switching circuit 124 may switch between imaging and therapy modes.
- compliant balloon 12 is configured to function as fluid lens, whereby the diameter of the focal ring (see 320 in FIG. 8A) can be varied with balloon pressure by changing the shape of balloon 12 with pressure and therewith changing the lens effect.
- the electronic focusing solution of FIG. 8A may be combined with the fluid lens balloon 12 of FIG. 8B.
- the focusing may be adjusted based on the bronchial diameter, corresponding to or matching the diameter of balloon 12, which can be calculated from balloon pressure or through ultrasound pinging, as described above with reference to FIGS. 10 and 11.
- a rotating transducer 11 may be incorporated into a mechanical intravascular ultrasound (IVUS) system (e.g., of Boston Scientific, BSX).
- IVUS intravascular ultrasound
- Therapeutic ultrasound pulses and/or full rotations may be interleaved with imaging pulses to generate quasi simultaneous imaging/therapy modes.
- the system (FIG. 1) circulating the coupling/cooling fluid might measure the fluid volume and or pressure and therewith determine the bronchial diameter (FIG. 10). Based on the measured bronchial diameter, the overall ultrasound power can be automatically optimized.
- FIG. 4A An additional application for the devices described above taking advantage of the energy dispersion characteristics (significant depth without undue near field damage; FIG. 4A) is lung tumor ablation.
- a guidewire is typically inserted under 3-dimensional guidance (i.e. Super Dimensions) in order to perform a biopsy.
- These systems combine 3D imaging with the localization of guidewires during bronchoscopy.
- treatment is typically performed later, in separate follow-up procedures.
- the guidewire may be used to advance the above-described ultrasound treatment catheter into the tumor.
- the ultrasound dose is calculated and one or more lesions are generated.
- the ablation is performed under image guidance.
- FIG. 12 provides image guidance of highest resolution which allows differentiation of tumor and normal tissues.
- a three element rotating annular array transducer 11" is shown.
- Another way to perform the tumor ablation, image guided, is to exchange treatment and imaging catheters over the guidewire.
- An IVUS imaging catheter may be advanced after withdrawal of the treatment catheter to monitor the tumor ablation progress and change back to the treatment catheter if the IVUS image shows non-ablated tumor regions.
- An additional application for the devices described above is reducing negative effects of ARDS caused by COVID 19 by optimizing utilization of the remaining healthy lung capacity by preventing or reducing bronchial contraction arid mucus secretion through denervation at the main bronchi.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Acoustics & Sound (AREA)
- Surgical Instruments (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022560322A JP2023520898A (en) | 2020-03-31 | 2021-01-29 | Bronchial denervation method using integrated A-mode signal |
CA3176126A CA3176126A1 (en) | 2020-03-31 | 2021-01-29 | Bronchial denervation using integrated a-mode signal |
US17/418,545 US20230135085A1 (en) | 2020-03-31 | 2021-01-29 | Bronchial denervation using integrated a-mode signal for optimization of ultrasound treatment |
AU2021246864A AU2021246864A1 (en) | 2020-03-31 | 2021-01-29 | Bronchial denervation using integrated A-mode signal |
KR1020227037765A KR20220162745A (en) | 2020-03-31 | 2021-01-29 | Bronchial denervation using integrated A-mode signal |
EP21779200.1A EP4125612A4 (en) | 2020-03-31 | 2021-01-29 | Bronchial denervation using integrated a-mode signal |
US17/350,848 US11607568B2 (en) | 2020-03-31 | 2021-06-17 | Method and apparatus for pulmonary interventions |
US17/391,486 US11565135B2 (en) | 2020-03-31 | 2021-08-02 | Method and apparatus for pulmonary interventions |
US17/954,549 US20230057488A1 (en) | 2020-03-31 | 2022-09-28 | Method and apparatus for pulmonary interventions |
US18/389,955 US20240123263A1 (en) | 2020-03-31 | 2023-12-20 | Bronchial denervation using integrated a-mode signal for optimization of ultrasound treatment |
US18/389,933 US20240123262A1 (en) | 2020-03-31 | 2023-12-20 | Bronchial denervation using integrated a-mode signal for optimization of ultrasound treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063002555P | 2020-03-31 | 2020-03-31 | |
US63/002,555 | 2020-03-31 |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/418,545 A-371-Of-International US20230135085A1 (en) | 2020-03-31 | 2021-01-29 | Bronchial denervation using integrated a-mode signal for optimization of ultrasound treatment |
US17/350,848 Continuation-In-Part US11607568B2 (en) | 2020-03-31 | 2021-06-17 | Method and apparatus for pulmonary interventions |
US18/389,933 Continuation US20240123262A1 (en) | 2020-03-31 | 2023-12-20 | Bronchial denervation using integrated a-mode signal for optimization of ultrasound treatment |
US18/389,955 Continuation US20240123263A1 (en) | 2020-03-31 | 2023-12-20 | Bronchial denervation using integrated a-mode signal for optimization of ultrasound treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021201963A1 true WO2021201963A1 (en) | 2021-10-07 |
Family
ID=77929458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/015825 WO2021201963A1 (en) | 2020-03-31 | 2021-01-29 | Bronchial denervation using integrated a-mode signal |
Country Status (7)
Country | Link |
---|---|
US (6) | US20230135085A1 (en) |
EP (1) | EP4125612A4 (en) |
JP (1) | JP2023520898A (en) |
KR (1) | KR20220162745A (en) |
AU (1) | AU2021246864A1 (en) |
CA (1) | CA3176126A1 (en) |
WO (1) | WO2021201963A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220162745A (en) * | 2020-03-31 | 2022-12-08 | 에어웨이브 메디컬 인코포레이티드 | Bronchial denervation using integrated A-mode signal |
CN115252060A (en) * | 2022-07-01 | 2022-11-01 | 深圳心寰科技有限公司 | Bronchial intervention ultrasonic treatment equipment and intervention method for treating chronic obstructive pneumonia |
WO2024081159A1 (en) * | 2022-10-14 | 2024-04-18 | AerWave Medical, Inc. | Method and apparatus for treatment of pulmonary conditions |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6984993B2 (en) * | 1999-04-28 | 2006-01-10 | Nexense Ltd. | Method and apparatus for making high-precision measurements |
US20140031727A1 (en) * | 2009-10-30 | 2014-01-30 | Sound Interventions, Inc. | Method and Apparatus for Treatment of Hypertension Through Percutaneous Ultrasound Renal Denervation |
WO2014022777A1 (en) * | 2012-08-03 | 2014-02-06 | Sound Interventions, Inc. | Method and apparatus for treatment of hypertension through an ultrasound imaging/therapy catheter |
WO2015066424A1 (en) * | 2013-11-04 | 2015-05-07 | Guided Interventions, Inc. | Method and apparatus for performance of thermal bronchiplasty with unfocused ultrasound |
US20160008636A1 (en) * | 2013-02-28 | 2016-01-14 | Guided Interventions, Inc. | Ultrasound imaging sheath and associated method for guided percutaneous trans-catheter therapy |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU760660B2 (en) * | 1999-03-02 | 2003-05-22 | Atrionix, Inc. | Atrial ablator having balloon and sensor |
US20130197555A1 (en) | 2002-07-01 | 2013-08-01 | Recor Medical, Inc. | Intraluminal devices and methods for denervation |
US20070066897A1 (en) | 2005-07-13 | 2007-03-22 | Sekins K M | Systems and methods for performing acoustic hemostasis of deep bleeding trauma in limbs |
US10828462B2 (en) * | 2009-06-01 | 2020-11-10 | Sanovas Intellectual Property, Llc | Systems and methods for impairing smooth muscle tissue function |
US9119951B2 (en) * | 2009-10-12 | 2015-09-01 | Kona Medical, Inc. | Energetic modulation of nerves |
US8469904B2 (en) | 2009-10-12 | 2013-06-25 | Kona Medical, Inc. | Energetic modulation of nerves |
US8986231B2 (en) * | 2009-10-12 | 2015-03-24 | Kona Medical, Inc. | Energetic modulation of nerves |
US8425455B2 (en) * | 2010-03-30 | 2013-04-23 | Angiodynamics, Inc. | Bronchial catheter and method of use |
US9192790B2 (en) | 2010-04-14 | 2015-11-24 | Boston Scientific Scimed, Inc. | Focused ultrasonic renal denervation |
EP2521593B1 (en) * | 2011-03-15 | 2015-12-09 | Kona Medical, Inc. | Energetic modulation of nerves |
WO2013048912A2 (en) | 2011-09-26 | 2013-04-04 | Guided Therapy Systems, Llc | Reflective ultrasound technology for dermatological treatments |
WO2015038886A1 (en) * | 2013-09-12 | 2015-03-19 | Holaira, Inc. | Systems, devices, and methods for treating a pulmonary disease with ultrasound energy |
US20180146839A1 (en) * | 2015-06-24 | 2018-05-31 | The Regents Of The University Of Colorado, A Body Corporate | Multi-use scope |
KR20220162745A (en) * | 2020-03-31 | 2022-12-08 | 에어웨이브 메디컬 인코포레이티드 | Bronchial denervation using integrated A-mode signal |
US11020618B1 (en) * | 2020-06-25 | 2021-06-01 | AerWave Medical, Inc. | Method and apparatus for performance of thermal bronchioplasty to reduce covid-19-induced respiratory distress and treat covid-19-damaged distal lung regions |
-
2021
- 2021-01-29 KR KR1020227037765A patent/KR20220162745A/en unknown
- 2021-01-29 EP EP21779200.1A patent/EP4125612A4/en active Pending
- 2021-01-29 US US17/418,545 patent/US20230135085A1/en active Pending
- 2021-01-29 JP JP2022560322A patent/JP2023520898A/en active Pending
- 2021-01-29 WO PCT/US2021/015825 patent/WO2021201963A1/en unknown
- 2021-01-29 CA CA3176126A patent/CA3176126A1/en active Pending
- 2021-01-29 AU AU2021246864A patent/AU2021246864A1/en active Pending
- 2021-06-17 US US17/350,848 patent/US11607568B2/en active Active
- 2021-08-02 US US17/391,486 patent/US11565135B2/en active Active
-
2022
- 2022-09-28 US US17/954,549 patent/US20230057488A1/en not_active Abandoned
-
2023
- 2023-12-20 US US18/389,933 patent/US20240123262A1/en active Pending
- 2023-12-20 US US18/389,955 patent/US20240123263A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6984993B2 (en) * | 1999-04-28 | 2006-01-10 | Nexense Ltd. | Method and apparatus for making high-precision measurements |
US20140031727A1 (en) * | 2009-10-30 | 2014-01-30 | Sound Interventions, Inc. | Method and Apparatus for Treatment of Hypertension Through Percutaneous Ultrasound Renal Denervation |
WO2014022777A1 (en) * | 2012-08-03 | 2014-02-06 | Sound Interventions, Inc. | Method and apparatus for treatment of hypertension through an ultrasound imaging/therapy catheter |
US20160008636A1 (en) * | 2013-02-28 | 2016-01-14 | Guided Interventions, Inc. | Ultrasound imaging sheath and associated method for guided percutaneous trans-catheter therapy |
WO2015066424A1 (en) * | 2013-11-04 | 2015-05-07 | Guided Interventions, Inc. | Method and apparatus for performance of thermal bronchiplasty with unfocused ultrasound |
Non-Patent Citations (1)
Title |
---|
See also references of EP4125612A4 * |
Also Published As
Publication number | Publication date |
---|---|
US20230135085A1 (en) | 2023-05-04 |
US20220008753A1 (en) | 2022-01-13 |
AU2021246864A1 (en) | 2022-11-03 |
EP4125612A4 (en) | 2024-04-24 |
JP2023520898A (en) | 2023-05-22 |
US20210316161A1 (en) | 2021-10-14 |
US20240123263A1 (en) | 2024-04-18 |
US20230057488A1 (en) | 2023-02-23 |
CA3176126A1 (en) | 2021-10-07 |
EP4125612A1 (en) | 2023-02-08 |
US20240123262A1 (en) | 2024-04-18 |
US11565135B2 (en) | 2023-01-31 |
US11607568B2 (en) | 2023-03-21 |
KR20220162745A (en) | 2022-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20160287912A1 (en) | Method and apparatus for performance of thermal bronchiplasty with unfocused ultrasound | |
US11185662B2 (en) | Method and apparatus for treatment of hypertension through percutaneous ultrasound renal denervation | |
US20240123263A1 (en) | Bronchial denervation using integrated a-mode signal for optimization of ultrasound treatment | |
US11273330B2 (en) | Method and apparatus for performance of thermal bronchioplasty to reduce COVID-19-induced respiratory distress and treat COVID-19-damaged distal lung regions | |
WO2024081158A2 (en) | Method and apparatus for treatment of pulmonary conditions | |
WO2024081159A1 (en) | Method and apparatus for treatment of pulmonary conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21779200 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3176126 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022560322 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227037765 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021246864 Country of ref document: AU Date of ref document: 20210129 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021779200 Country of ref document: EP Effective date: 20221031 |